'In the weeds': navigating the complex concerns, challenges and choices associated with medicinal cannabis consumption for endometriosis.

IF 3.4 Q2 REPRODUCTIVE BIOLOGY
Reproduction & fertility Pub Date : 2025-06-12 Print Date: 2025-04-01 DOI:10.1530/RAF-24-0098
Justin Sinclair, Allie Eathorne, Hannah Adler, Amelia Mardon, Orit Holtzman, Jason Abbott, Jerome Sarris, Mike Armour
{"title":"'In the weeds': navigating the complex concerns, challenges and choices associated with medicinal cannabis consumption for endometriosis.","authors":"Justin Sinclair, Allie Eathorne, Hannah Adler, Amelia Mardon, Orit Holtzman, Jason Abbott, Jerome Sarris, Mike Armour","doi":"10.1530/RAF-24-0098","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>People with endometriosis report consuming cannabis to manage their symptoms. Given the range of differing legalities and access pathways across the world, this study aimed to investigate the drivers and barriers to cannabis use worldwide. An online, anonymous, cross-sectional survey was distributed internationally by endometriosis organisations and was open to anyone consuming cannabis for endometriosis symptoms. Survey questions included motivations for both starting and ongoing cannabis consumption, concerns over cannabis use, reasons for stopping cannabis, and communication of cannabis consumption with healthcare providers. Eight hundred and eighty-nine responses were collected across >10 countries. Illicit cannabis (56.7%) was the most common access pathway. 99% of respondents stated they would continue to use cannabis to manage their endometriosis-based symptoms, with 90% reporting they would recommend its use to a friend or relative with the disease. The most common motivation(s) for cannabis consumption were inadequate pain control (68.6%) and bothersome side effects of medications (56.3%). Similar motivations were reported for ongoing cannabis consumption, with concerns over dependence/addiction on pharmaceutical medications (43.9%) being another common motivation. Those using illicit cannabis were significantly less likely (P < 0.0001) to disclose their cannabis consumption to medical professionals. Cannabis was viewed as superior to pharmaceuticals both in terms of effectiveness and side-effect profile. Despite this, concerns around cost, breaking the law, judgement due to stigma, and current drug-driving laws were reported. Illicit usage and lack of medical oversight raise concerns over potential drug interactions or withdrawal effects due to reduction in pharmaceutical medications because of cannabis.</p><p><strong>Lay summary: </strong>Survey participants reported that it is most common internationally for people using cannabis to manage endometriosis pain and associated symptoms to access this illegally, despite medical access being available in many countries. Many respondents also reported that cannabis was more effective and had a more tolerable side-effect profile than pharmaceutical medications they had used previously. However, over half of respondents were concerned about the negative impact of stigma associated with cannabis and how this might affect their day-to-day lives. Other concerns were potentially breaking the law where they live, possibly losing their driving licence due to drug-driving laws, or losing their job due to workplace drug-testing policies. Such concerns may be why more than 30% of participants reported not disclosing their cannabis consumption to their doctor. This is concerning because medical supervision is important to monitor for side effects and potential drug interactions, which people using cannabis may not know exist.</p>","PeriodicalId":101312,"journal":{"name":"Reproduction & fertility","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164284/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproduction & fertility","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1530/RAF-24-0098","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: People with endometriosis report consuming cannabis to manage their symptoms. Given the range of differing legalities and access pathways across the world, this study aimed to investigate the drivers and barriers to cannabis use worldwide. An online, anonymous, cross-sectional survey was distributed internationally by endometriosis organisations and was open to anyone consuming cannabis for endometriosis symptoms. Survey questions included motivations for both starting and ongoing cannabis consumption, concerns over cannabis use, reasons for stopping cannabis, and communication of cannabis consumption with healthcare providers. Eight hundred and eighty-nine responses were collected across >10 countries. Illicit cannabis (56.7%) was the most common access pathway. 99% of respondents stated they would continue to use cannabis to manage their endometriosis-based symptoms, with 90% reporting they would recommend its use to a friend or relative with the disease. The most common motivation(s) for cannabis consumption were inadequate pain control (68.6%) and bothersome side effects of medications (56.3%). Similar motivations were reported for ongoing cannabis consumption, with concerns over dependence/addiction on pharmaceutical medications (43.9%) being another common motivation. Those using illicit cannabis were significantly less likely (P < 0.0001) to disclose their cannabis consumption to medical professionals. Cannabis was viewed as superior to pharmaceuticals both in terms of effectiveness and side-effect profile. Despite this, concerns around cost, breaking the law, judgement due to stigma, and current drug-driving laws were reported. Illicit usage and lack of medical oversight raise concerns over potential drug interactions or withdrawal effects due to reduction in pharmaceutical medications because of cannabis.

Lay summary: Survey participants reported that it is most common internationally for people using cannabis to manage endometriosis pain and associated symptoms to access this illegally, despite medical access being available in many countries. Many respondents also reported that cannabis was more effective and had a more tolerable side-effect profile than pharmaceutical medications they had used previously. However, over half of respondents were concerned about the negative impact of stigma associated with cannabis and how this might affect their day-to-day lives. Other concerns were potentially breaking the law where they live, possibly losing their driving licence due to drug-driving laws, or losing their job due to workplace drug-testing policies. Such concerns may be why more than 30% of participants reported not disclosing their cannabis consumption to their doctor. This is concerning because medical supervision is important to monitor for side effects and potential drug interactions, which people using cannabis may not know exist.

“在杂草中”:浏览与子宫内膜异位症药用大麻消费相关的复杂问题、挑战和选择。
患有子宫内膜异位症的人报告服用大麻来控制他们的症状。鉴于世界各地的合法性和获取途径不同,本研究旨在调查全球大麻的驱动因素和障碍。子宫内膜异位症组织在全球范围内进行了一项在线、匿名、横断面调查,对因子宫内膜异位症症状而吸食大麻的任何人开放。调查问题包括开始和持续吸食大麻的动机、对吸食大麻的关切、停止吸食大麻的原因以及吸食大麻与保健提供者的沟通情况。在10个国家收集了889份回复。非法大麻(56.7%)是最常见的获取途径。99%的受访者表示,他们将继续利用大麻来控制子宫内膜异位症的症状,90%的受访者表示,他们会向患有这种疾病的朋友或亲戚推荐大麻。吸食大麻最常见的动机是疼痛控制不足(68.6%)和令人烦恼的药物副作用(56.3%)。据报告,持续吸食大麻的动机类似,对药物依赖/成瘾的担忧(43.9%)是另一个常见动机。那些使用非法大麻的人明显不太可能(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信